Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Commentary|Articles|May 15, 2025
Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting
Author(s)Ashley Chan
Fact checked by: Caroline Seymour
Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.
Advertisement
Advertisement
With the
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Advertisement
Advertisement